Cobra Biologics is an international contract development and manufacturing organisation (CDMO) of biologics and pharmaceuticals for clinical and commercial supply. Cobra has three GMP approved facilities, each with expertise tailored to serving our customers across the world. We offer a broad range of integrated and stand-alone contract services, from cell line and process development through to fill and finish for investigational medicinal products and commercial production.
For over 16 years we have taken pride in being a trusted manufacturing provider, delivering what we promise and helping our customers to develop medicines for the benefit of patients. Cobra provides manufacturing technologies, platforms and solutions to the life science industry covering antibodies, recombinant proteins, viruses, phage, DNA, whole cell vaccines and therapeutics as well as biologics and small molecule API lyophilisation and fill finish.
Cobra’s MaxXpress service optimises cell-line development using a unique technology that infuses Ubiquitous Chromatin-Opening Element (UCOE) technology with cell-line development expertise to yield increased recombinant protein and antibody production. 100-300mg of material can be produced in under 10 weeks.
Cobra also uses microbioreactor technology (Ambr™, Tap BioSystems) for evaluation of process parameters. The better monitoring, process control capability and speed (weeks not months), compared to shake flask culture or bioreactors, is a significant advantage and allows data on the cells’ behaviour and product characteristics to be collected before larger bioreactor studies. This ensures superior product similarity to that achieved in a large scale bioreactor.
At Cobra, we recognise the value of transparent and effective communications with our customers. We provide regular progress updates and respond to our customers’ needs. Large enough to deliver and small enough to care, Cobra dedicates the attention and resources needed with multidisciplinary teams that remain with each program throughout its life. This seamless integration reduces both transfer risk and time delays, thereby increasing customer satisfaction. Delivering the highest quality products on schedule through trusted relationships ensures that our customers come back for further clinical development and production or with new projects.
Find out more and take a virtual tour of Cobra’s GMP approved facilities in Sweden and the UK: www.cobrabio.com
Contact Magnus Gustafsson on +46 70 723 1010 or email email@example.com